// startup autopsy
Exscientia
The AI drug discovery pioneer that brought the first AI-designed drugs to trials and was acquired at a 75 percent discount
acquisition gone wrongFire Sale
Distressed acquisition below last-round valuation · Fatal mistake: Timing
// the model, blind
Evaluating only Exscientia’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Acquisition gone wrong.
Key Events Timeline
FOUNDING
Exscientia founded by Andrew Hopkins to pioneer AI-driven drug discovery in Oxford, UK.
PRODUCT LAUNCH
Exscientia announced first AI-designed drug molecule entering human clinical trials, a major scientific milestone in computational drug discovery.
FUNDING
Exscientia completed IPO on NASDAQ valuing the company at 2.9 billion dollars with strong investor enthusiasm for AI drug discovery.
DOWN ROUND
Stock price declined significantly from IPO peak of 25 dollars as market realized AI drug discovery faces commercialization challenges.
LAYOFF
Exscientia announced workforce reductions as revenue generation failed to meet investor expectations and cash burn accelerated.
ACQUISITION ATTEMPT
Recursion Pharmaceuticals acquired Exscientia for 688 million dollars, a 76 percent decline from its 2.9 billion dollar IPO valuation.